Letter to the Editor: Serum alpha-fetoprotein dynamics in liver failure - prognostic implications and clinical insights

Abstract

Alpha-fetoprotein (AFP), which is re-expressed during hepatocyte regeneration, may serve as a surrogate marker of hepatic recovery in liver failure. We read with great interest the study by Guo et al. This study suggests that dynamic changes in serum AFP possesses potential prognostic value in patients with liver failure undergoing artificial liver support. Despite the limitations of a small sample size and lack of mechanistic validation, the findings nonetheless suggest that AFP holds potential for risk stratification and future individualized treatment. Future studies should emphasize multicenter prospective validation, integration with multidimensional biomarkers, and mechanistic investigation of AFP-related signaling pathways. In this letter, we summarize the established roles of AFP-associated pathways in liver regeneration. Further elucidation of AFP signaling may contribute to more effective strategies for precision artificial liver therapy and improved prognostic assessment.

Keywords: Liver failure; Alpha-fetoprotein; Prognostic prediction; Acute-on-chronic liver failure; Hepatic regeneration; Wnt/β-catenin; STAT3; Immune response

Core Tip: Guo et al highlighted that serum alpha-fetoprotein (AFP) kinetics may serve as an important prognostic indicator for patients with liver failure and help stratify risk in those receiving artificial liver support therapy. Despite limitations such as a small sample size and a lack of mechanistic validation, dynamic changes in AFP remain a promising complement to traditional prognostic scores. Future research should prioritize multicenter prospective validation and integrate AFP kinetics with multidimensional biomarkers and existing prognostic models, while also exploring regeneration-related signaling such as Wnt/β-catenin, STAT3, and immune pathways.